DE60219917D1 - Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen - Google Patents
Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungenInfo
- Publication number
- DE60219917D1 DE60219917D1 DE60219917T DE60219917T DE60219917D1 DE 60219917 D1 DE60219917 D1 DE 60219917D1 DE 60219917 T DE60219917 T DE 60219917T DE 60219917 T DE60219917 T DE 60219917T DE 60219917 D1 DE60219917 D1 DE 60219917D1
- Authority
- DE
- Germany
- Prior art keywords
- alzheimer
- treatment
- inhibitors
- tau aggregation
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0117326.9A GB0117326D0 (en) | 2001-07-16 | 2001-07-16 | Napthoquinone-type inhibitors of protein aggregation |
GB0117326 | 2001-07-16 | ||
PCT/GB2002/003269 WO2003007933A1 (en) | 2001-07-16 | 2002-07-16 | Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60219917D1 true DE60219917D1 (de) | 2007-06-14 |
DE60219917T2 DE60219917T2 (de) | 2008-01-17 |
Family
ID=9918593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60219917T Expired - Lifetime DE60219917T2 (de) | 2001-07-16 | 2002-07-16 | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen |
Country Status (13)
Country | Link |
---|---|
US (1) | US7605179B2 (de) |
EP (1) | EP1408952B1 (de) |
JP (1) | JP5147157B2 (de) |
CN (1) | CN1313088C (de) |
AT (1) | ATE361067T1 (de) |
AU (1) | AU2002317354B2 (de) |
CA (1) | CA2451422C (de) |
DE (1) | DE60219917T2 (de) |
ES (1) | ES2287292T3 (de) |
GB (1) | GB0117326D0 (de) |
HK (1) | HK1063012A1 (de) |
SG (1) | SG148846A1 (de) |
WO (1) | WO2003007933A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
MXPA05013692A (es) * | 2003-06-23 | 2006-03-13 | Neurochem Int Ltd | Metodos para tratar trastornos por acumulacion de proteina. |
WO2005053609A2 (en) * | 2003-11-26 | 2005-06-16 | Guilford Pharmaceuticals Inc. | Methods of nad+-dependent deacetylase inhibitors |
WO2006007864A1 (en) * | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
FR2874923B1 (fr) * | 2004-09-07 | 2006-10-27 | Trophos Sa | Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation |
JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
JP4734602B2 (ja) | 2004-12-21 | 2011-07-27 | Dowaエレクトロニクス株式会社 | 保存安定性に優れた窒化鉄系磁性粉末 |
JP4822312B2 (ja) * | 2005-05-13 | 2011-11-24 | 学校法人慶應義塾 | ナフトキノン誘導体化合物 |
KR100699945B1 (ko) * | 2005-11-24 | 2007-03-26 | (주) 디지탈바이오텍 | 나프토퀴논계 화합물을 함유하는 인지기능 장애의 예방 및 치료용 조성물 |
PL2004155T3 (pl) | 2006-03-29 | 2018-08-31 | Wista Laboratories Ltd. | Inhibitory agregacji białek |
PT2013191E (pt) | 2006-03-29 | 2010-10-29 | Wista Lab Ltd | Sais de 3,7-diamino-10h-fenotiazina e a sua utilização |
CA2655632A1 (en) * | 2006-06-23 | 2008-01-03 | The Feinstein Institute For Medical Research | Inhibitors of a.beta. and synuclein aggregation |
EP2130533A4 (de) * | 2007-04-05 | 2010-04-21 | J Oil Mills Inc | Ataraktikum und funktionelles nahrungsmittel |
WO2009033151A1 (en) * | 2007-09-07 | 2009-03-12 | The Trustees Of Columbia University In The City Of New York | Tau protein screening assay |
EP2060256A1 (de) * | 2007-11-16 | 2009-05-20 | Gnosis S.p.A. | Auf Menaquinolen basierende pharmazeutische und nutrazeutische Zusammensetzungen |
GB0816269D0 (en) * | 2008-09-05 | 2008-10-15 | Univ Ramot | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease |
WO2011119842A1 (en) | 2010-03-25 | 2011-09-29 | The J. David Gladstone Institutes | Compositions and methods for treating neurological disorders |
US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
WO2012019029A2 (en) * | 2010-08-06 | 2012-02-09 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with naphthoquinones |
CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
ES2594703T3 (es) | 2011-02-11 | 2016-12-22 | Wista Laboratories Ltd. | Sales de fenotiazin diamonio y sus usos |
CA2831331C (en) | 2011-04-21 | 2019-10-15 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
WO2013051266A1 (ja) | 2011-10-03 | 2013-04-11 | 独立行政法人国立長寿医療研究センター | タウ凝集阻害剤 |
WO2013115867A1 (en) | 2012-02-05 | 2013-08-08 | Biodesy, Llc | Methods for identifying modulators of ras using nonlinear techniques |
US9567395B2 (en) | 2012-08-16 | 2017-02-14 | Ipierian, Inc. | Methods of treating a tauopathy |
US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
LT2914291T (lt) | 2012-11-02 | 2022-06-10 | Bioverativ Usa Inc. | Antikūnai prieš komplemento c1s ir jų panaudojimo būdai |
WO2014162737A1 (ja) | 2013-04-02 | 2014-10-09 | 学校法人同志社 | タウ凝集阻害剤 |
CN105339002B (zh) | 2013-06-10 | 2019-06-28 | 伊皮埃里安股份有限公司 | 治疗tau病变的方法 |
JP6518656B2 (ja) * | 2013-06-13 | 2019-05-22 | バイオデシー, インコーポレイテッド | 標的生体実体を標的にする生化学実体候補をスクリーニングする方法 |
US20150166476A1 (en) * | 2013-12-17 | 2015-06-18 | Yi-Cheng Chen | Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta |
EP3237906B8 (de) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion |
WO2019191773A1 (en) | 2018-03-30 | 2019-10-03 | Kaydence Pharma As | Rapidly improving vascular conditions by administering vitamin k |
WO2020201828A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
CN110025624B (zh) * | 2019-05-29 | 2021-04-02 | 济宁医学院附属医院 | 萘醌苷类化合物在老年痴呆中的应用及其药物制备 |
CN112778092B (zh) * | 2020-12-31 | 2023-03-24 | 玉溪健坤生物药业有限公司 | 一种还原型维生素k2的制备方法及其用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59175449A (ja) * | 1983-03-26 | 1984-10-04 | Kyushu Kogyo Daigaku | シコニンの製造法 |
JPS61143334A (ja) * | 1984-12-18 | 1986-07-01 | Mitsui Petrochem Ind Ltd | 5,8−ジヒドロキシ−1,4−ナフトキノン誘導体 |
US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
DE69231222T2 (de) * | 1991-02-04 | 2001-03-01 | Ks Biomedix Ltd | Naphtochinonderivate zur Behandlung von chronischen Entzündungen |
ATE386115T1 (de) | 1991-12-06 | 2008-03-15 | Max Planck Gesellschaft | Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit |
AU708682B2 (en) | 1994-08-08 | 1999-08-12 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes |
JPH08193026A (ja) * | 1995-01-12 | 1996-07-30 | Teijin Ltd | アミロイドβ蛋白凝集・沈着阻害剤 |
DE19504003A1 (de) * | 1995-02-08 | 1996-08-14 | Martin Dr Kohlmeier | Verwendungen eines Vitamins der K-Gruppe |
GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
KR0180791B1 (ko) * | 1995-07-24 | 1999-05-15 | 김용옥 | 6-치환-5,8-디옥시-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도 |
JP3809014B2 (ja) * | 1998-05-22 | 2006-08-16 | 花王株式会社 | 養毛・育毛剤 |
US20020040011A1 (en) * | 2000-06-01 | 2002-04-04 | Brown Dennis M. | Naphthoquinone compositions and uses thereof |
US20020016372A1 (en) * | 2000-07-31 | 2002-02-07 | Allison Anthony Clifford | Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
DK2322517T3 (da) | 2004-09-23 | 2019-06-11 | Wista Lab Ltd | Fremgangsmåder til kemisk syntese og oprensning af diaminophenothiaziniumforbindelser med methylthioniniumchlorid (mtc) |
-
2001
- 2001-07-16 GB GBGB0117326.9A patent/GB0117326D0/en not_active Ceased
-
2002
- 2002-07-16 JP JP2003513541A patent/JP5147157B2/ja not_active Expired - Lifetime
- 2002-07-16 US US10/483,266 patent/US7605179B2/en not_active Expired - Lifetime
- 2002-07-16 SG SG200600959-1A patent/SG148846A1/en unknown
- 2002-07-16 DE DE60219917T patent/DE60219917T2/de not_active Expired - Lifetime
- 2002-07-16 AU AU2002317354A patent/AU2002317354B2/en not_active Expired
- 2002-07-16 CA CA2451422A patent/CA2451422C/en not_active Expired - Lifetime
- 2002-07-16 ES ES02745640T patent/ES2287292T3/es not_active Expired - Lifetime
- 2002-07-16 AT AT02745640T patent/ATE361067T1/de active
- 2002-07-16 EP EP02745640A patent/EP1408952B1/de not_active Expired - Lifetime
- 2002-07-16 WO PCT/GB2002/003269 patent/WO2003007933A1/en active IP Right Grant
- 2002-07-16 CN CNB028177207A patent/CN1313088C/zh not_active Expired - Lifetime
-
2004
- 2004-07-24 HK HK04105484A patent/HK1063012A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1063012A1 (en) | 2004-12-10 |
AU2002317354B2 (en) | 2007-07-19 |
EP1408952B1 (de) | 2007-05-02 |
ATE361067T1 (de) | 2007-05-15 |
JP2004534854A (ja) | 2004-11-18 |
GB0117326D0 (en) | 2001-09-05 |
US20050107472A1 (en) | 2005-05-19 |
JP5147157B2 (ja) | 2013-02-20 |
CA2451422A1 (en) | 2003-01-30 |
WO2003007933A1 (en) | 2003-01-30 |
CN1553800A (zh) | 2004-12-08 |
DE60219917T2 (de) | 2008-01-17 |
CN1313088C (zh) | 2007-05-02 |
SG148846A1 (en) | 2009-01-29 |
EP1408952A1 (de) | 2004-04-21 |
ES2287292T3 (es) | 2007-12-16 |
CA2451422C (en) | 2010-10-19 |
US7605179B2 (en) | 2009-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60219917D1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
NO20053855D0 (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
DE122012000007I1 (de) | Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung. | |
DK1465626T3 (da) | Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf | |
NO20071240L (no) | Terapeutiske anvendelser av RTP801 inhibitorer | |
ES2170104T3 (es) | Inhibidores de la produccion de proteinas de beta-amiloide. | |
EA200501017A1 (ru) | Астма и модуляторы аллергических воспалений | |
WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
ATE554756T1 (de) | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen | |
NO20063193L (no) | Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav | |
ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
DE60237635D1 (de) | Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose | |
ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
ATE553114T1 (de) | Verbindungen zur verminderung der aggregation von amyloid-beta-peptid | |
BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
DE602004024992D1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten | |
DE602004014115D1 (de) | Neue amidderivate von 2,2,3,3-tetramethylcyclopropancarbonsäure | |
MY135225A (en) | Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders | |
ATE528299T1 (de) | Cyclische ketale als beta-sekretase-inhibitoren zur behandlung von alzheimer-krankheit | |
ATE465175T1 (de) | Neuer proteinkomplex und anwendungen davon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |